|
1
|
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
|
Clin Infect Dis
|
2009
|
22.98
|
|
2
|
Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.
|
N Engl J Med
|
2005
|
8.39
|
|
3
|
Combating antimicrobial resistance: policy recommendations to save lives.
|
Clin Infect Dis
|
2011
|
5.58
|
|
4
|
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.
|
PLoS Pathog
|
2009
|
3.05
|
|
5
|
Nosocomial fungal infections: epidemiology, diagnosis, and treatment.
|
Med Mycol
|
2007
|
3.02
|
|
6
|
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.
|
Clin Infect Dis
|
2008
|
2.63
|
|
7
|
Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.
|
Antimicrob Agents Chemother
|
2005
|
2.54
|
|
8
|
Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.
|
Clin Infect Dis
|
2007
|
2.17
|
|
9
|
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.
|
MBio
|
2012
|
2.15
|
|
10
|
Pathogenesis of mucormycosis.
|
Clin Infect Dis
|
2012
|
2.14
|
|
11
|
Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.
|
Antimicrob Agents Chemother
|
2003
|
2.01
|
|
12
|
Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
|
J Antimicrob Chemother
|
2006
|
1.99
|
|
13
|
Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target.
|
J Infect Dis
|
2010
|
1.96
|
|
14
|
Progress toward a Staphylococcus aureus vaccine.
|
Clin Infect Dis
|
2011
|
1.72
|
|
15
|
Dr. William H. Stewart: mistaken or maligned?
|
Clin Infect Dis
|
2008
|
1.71
|
|
16
|
Seven ways to preserve the miracle of antibiotics.
|
Clin Infect Dis
|
2013
|
1.63
|
|
17
|
Combination echinocandin-polyene treatment of murine mucormycosis.
|
Antimicrob Agents Chemother
|
2008
|
1.43
|
|
18
|
Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro.
|
Infect Immun
|
2005
|
1.42
|
|
19
|
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
|
Antimicrob Agents Chemother
|
2006
|
1.40
|
|
20
|
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
|
Curr Opin Infect Dis
|
2008
|
1.38
|
|
21
|
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.
|
J Clin Invest
|
2010
|
1.34
|
|
22
|
Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection.
|
PLoS One
|
2012
|
1.32
|
|
23
|
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis.
|
Mol Microbiol
|
2010
|
1.27
|
|
24
|
The FDA reboot of antibiotic development.
|
Antimicrob Agents Chemother
|
2013
|
1.22
|
|
25
|
To treat or not to treat: adjunctive antibiotics for uncomplicated abscesses.
|
Ann Emerg Med
|
2011
|
1.17
|
|
26
|
Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
|
Clin Infect Dis
|
2010
|
1.16
|
|
27
|
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
|
Antimicrob Agents Chemother
|
2008
|
1.15
|
|
28
|
The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
|
Nat Rev Drug Discov
|
2012
|
1.13
|
|
29
|
Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene.
|
FEMS Microbiol Lett
|
2004
|
1.11
|
|
30
|
Voriconazole use for endemic fungal infections.
|
Antimicrob Agents Chemother
|
2009
|
1.10
|
|
31
|
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
|
J Antimicrob Chemother
|
2009
|
1.08
|
|
32
|
End points in trials of treatments for skin infections.
|
JAMA
|
2013
|
1.07
|
|
33
|
The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.
|
Infect Immun
|
2013
|
1.06
|
|
34
|
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
|
Clin Infect Dis
|
2012
|
1.05
|
|
35
|
Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus.
|
FEMS Immunol Med Microbiol
|
2009
|
1.05
|
|
36
|
Antibacterial resistance leadership group: open for business.
|
Clin Infect Dis
|
2014
|
1.04
|
|
37
|
Community-acquired pneumonia.
|
N Engl J Med
|
2014
|
1.02
|
|
38
|
Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.
|
Vaccine
|
2012
|
1.01
|
|
39
|
Local inflammation exacerbates the severity of Staphylococcus aureus skin infection.
|
PLoS One
|
2013
|
0.99
|
|
40
|
Comparison of lipid amphotericin B preparations in treating murine zygomycosis.
|
Antimicrob Agents Chemother
|
2008
|
0.98
|
|
41
|
Diabetic murine models for Acinetobacter baumannii infection.
|
J Antimicrob Chemother
|
2012
|
0.98
|
|
42
|
Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein.
|
J Infect Dis
|
2010
|
0.96
|
|
43
|
Future directions in mucormycosis research.
|
Clin Infect Dis
|
2012
|
0.95
|
|
44
|
Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.
|
Clin Vaccine Immunol
|
2008
|
0.95
|
|
45
|
Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.
|
J Infect Dis
|
2008
|
0.95
|
|
46
|
Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
|
Antimicrob Agents Chemother
|
2011
|
0.93
|
|
47
|
Acute bacterial skin and skin structure infection trials: the bad is the enemy of the good.
|
Clin Infect Dis
|
2011
|
0.88
|
|
48
|
Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.
|
Infect Control Hosp Epidemiol
|
2011
|
0.88
|
|
49
|
"Airborne assault": a new dimension in Acinetobacter baumannii transmission*.
|
Crit Care Med
|
2013
|
0.88
|
|
50
|
Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.
|
Clin Infect Dis
|
2012
|
0.88
|
|
51
|
Lack of cross-hepatotoxicity between fluconazole and voriconazole.
|
Clin Infect Dis
|
2003
|
0.85
|
|
52
|
Does real-time feedback to residents with or without attendings improve medical documentation?
|
Hosp Pract (1995)
|
2014
|
0.85
|
|
53
|
Overcoming the challenges to developing new antibiotics.
|
Curr Opin Pharmacol
|
2012
|
0.85
|
|
54
|
Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?
|
Med Mycol
|
2009
|
0.84
|
|
55
|
Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
|
Antimicrob Agents Chemother
|
2006
|
0.83
|
|
56
|
Safety and efficacy of activated transfected killer cells for neutropenic fungal infections.
|
J Infect Dis
|
2010
|
0.82
|
|
57
|
Antibiotic resistance and antibiotic development.
|
Lancet Infect Dis
|
2008
|
0.82
|
|
58
|
The future of antibiotics.
|
Crit Care
|
2014
|
0.80
|
|
59
|
Impact of hospital variables on case mix index as a marker of disease severity.
|
Popul Health Manag
|
2013
|
0.80
|
|
60
|
Mucormycosis, pseudallescheriasis, and other uncommon mold infections.
|
Proc Am Thorac Soc
|
2010
|
0.79
|
|
61
|
Luminescent-activated transfected killer cells to monitor leukocyte trafficking during systemic bacterial and fungal infection.
|
J Infect Dis
|
2011
|
0.79
|
|
62
|
Prospects for and barriers to a fungal vaccine.
|
Expert Opin Biol Ther
|
2007
|
0.78
|
|
63
|
Amphotericin B: is a lipid-formulation gold standard feasible?
|
Clin Infect Dis
|
2004
|
0.78
|
|
64
|
Routine CSF analysis in coccidioidomycosis is not required.
|
PLoS One
|
2013
|
0.77
|
|
65
|
Immunoglobulin G2 antibodies and HIV-infected long-term nonprogressors: what is the mechanism?
|
J Infect Dis
|
2006
|
0.76
|
|
66
|
Skin and soft-tissue infections: modern evolution of an ancient problem.
|
Clin Infect Dis
|
2010
|
0.76
|
|
67
|
Geographic differences in Medicare spending.
|
N Engl J Med
|
2010
|
0.75
|
|
68
|
Is computed tomography of the head useful before lumbar puncture?
|
Clin Infect Dis
|
2005
|
0.75
|
|
69
|
Treatment of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections with drainage but no antibiotic therapy.
|
Pediatr Infect Dis J
|
2004
|
0.75
|
|
70
|
Spider bites and infections caused by community-associated methicillin-resistant Staphylococcus aureus.
|
Surg Infect (Larchmt)
|
2004
|
0.75
|
|
71
|
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.
|
J Comp Eff Res
|
2015
|
0.75
|
|
72
|
Change in intern calls at night after a work hour restriction process change.
|
JAMA Intern Med
|
2013
|
0.75
|